NCT06662227View on ClinicalTrials.gov

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2029

Conditions

B Cell LymphomaB Cell LeukemiaB Cell Malignancy

Interventions

BIOLOGICAL

Single dose injection of certain dose of UWD-19

Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-19 cells

Trial Locations (1)

710061

RECRUITING

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an